381 related articles for article (PubMed ID: 27397043)
1. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
2. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.
Ansell SM
Lancet Haematol; 2019 Jan; 6(1):e2-e3. PubMed ID: 30612711
[No Abstract] [Full Text] [Related]
3. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
Dada R
Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
[TBL] [Abstract][Full Text] [Related]
4. Making precision oncology the standard of care.
The Lancet Oncology
Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
[No Abstract] [Full Text] [Related]
5. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
Kwong YL; Lopes D; Khong PL
Br J Haematol; 2017 Jan; 176(1):131-132. PubMed ID: 26773814
[No Abstract] [Full Text] [Related]
6. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma.
Lee JJ; Chan A; Tang T
Acta Oncol; 2016; 55(4):519-20. PubMed ID: 26754959
[No Abstract] [Full Text] [Related]
7. Pembrolizumab in classical Hodgkin's lymphoma.
Maly J; Alinari L
Eur J Haematol; 2016 Sep; 97(3):219-27. PubMed ID: 27147112
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab activity in relapsed Hodgkin's lymphoma.
Das M
Lancet Oncol; 2017 Apr; 18(4):e205. PubMed ID: 28318993
[No Abstract] [Full Text] [Related]
9. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
10. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
11. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
12. Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Sim JPY; Au-Yeung R; Kwong YL
Ann Hematol; 2020 Feb; 99(2):385-388. PubMed ID: 31773213
[No Abstract] [Full Text] [Related]
13. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
14. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
Peters S; Kerr KM; Stahel R
Cancer Treat Rev; 2018 Jan; 62():39-49. PubMed ID: 29156447
[TBL] [Abstract][Full Text] [Related]
16. Resistance to PD-1 blockade in melanoma.
Burki TK
Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
[No Abstract] [Full Text] [Related]
17. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody.
Michot JM; Mazeron R; Dercle L; Ammari S; Canova C; Marabelle A; Rose S; Rubin E; Deutsch E; Soria JC; Ribrag V; Levy A
Eur J Cancer; 2016 Oct; 66():91-4. PubMed ID: 27544928
[No Abstract] [Full Text] [Related]
18. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.
Dercle L; Ammari S; Seban RD; Schwartz LH; Houot R; Labaied N; Mokrane FZ; Lazarovici J; Danu A; Marabelle A; Ribrag V; Michot JM
Eur J Cancer; 2018 Mar; 91():136-144. PubMed ID: 29360605
[TBL] [Abstract][Full Text] [Related]
19. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
20. Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab.
Rogatsch M; Schmid J; Lax S; Uranitsch M; Schmid-Zalaudek K; Giuffrida R; Zalaudek I
Eur J Cancer; 2018 Feb; 90():146-148. PubMed ID: 29237537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
